merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>FDA-approved, lower-cost vials offer safer, legitimate alternative that makes compounded versions less attractive</answer>
<question_number>2</question_number>
<answer>providing telehealth prescribing and home delivery of branded vials through LillyDirect, duplicating the convenience that telehealth compounding firms rely on</answer>
<question_number>3</question_number>
<answer>lack of FDA oversight leading to safety, quality and effectiveness concerns</answer>
<question_number>4</question_number>
<answer>undercuts compounders’ prices to lure customers back to Lilly products even if some pen users switch</answer>
<question_number>5</question_number>
<answer>being on the FDA shortage list lets compounders copy tirzepatide; removal would support Lilly’s legal bid to stop them</answer>
<question_number>6</question_number>
<answer>direct sales with “transparent pricing” by bypassing third-party supply chains</answer>
<question_number>7</question_number>
<answer>Medicare patients may self-pay for vials despite heightened health risks</answer>
<question_number>8</question_number>
<answer>signals an FDA-sanctioned, safer choice likely to shift perceptions away from compounded drugs</answer>
<question_number>9</question_number>
<answer>listed as “in shortage” by the FDA</answer>
<question_number>10</question_number>
<answer>aggressive price reduction</answer>